Replies to post #432 on The Moon Phase

[PoemStone]

OREX. Orexigen Therapeutics Receives Dispute Response Indicating FDA is Highly Supportive of Exploration of a Faster Path to Resubmission of the Contrave NDA
-- Light Study enrollment surpasses 7,000 patients; the Company plans to continue enrollment to approximately 9,000 patients by year end, speeding the time to interim analysis
http://finance.yahoo.com/news/orexigen-therapeutics-receives-dispute-response-110200473.html